Evidence map›Paper›PMID 32631441›Full record

ArticleActa neuropathologica communications2020

Disturbed balance in the expression of MMP9 and TIMP3 in cerebral amyloid angiopathy-related intracerebral haemorrhage.

Lieke Jäkel, H Bea Kuiperij, Lara P Gerding, Emma E M Custers, Emma van den Berg, Wilmar M T Jolink, Floris H B M Schreuder, Benno Küsters, Catharina J M Klijn, Marcel M Verbeek

Open access · goldAbstract read
In one paragraph

Article in Acta neuropathologica communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
2.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. Prevalence of cerebral amyloid angiopathy: A systematic review and meta-analysis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022
    Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Use of anti-amyloid-β monoclonal antibodies in persons with Down syndrome Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. The role of MMPs in intracerebral hemorrhage.Frontiers in cell and developmental biology · 2025
    Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Lieke JäkelDepartment of Laboratory Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
H Bea KuiperijDepartment of Laboratory Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
Lara P GerdingDepartment of Laboratory Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
Emma E M CustersDepartment of Laboratory Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
Emma van den BergDepartment of Laboratory Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
Wilmar M T JolinkDepartment of Neurology and Neurosurgery, University Medical Center Utrecht Brain Center, Utrecht University, Utrecht, The Netherlands.
Floris H B M SchreuderDepartment of Neurology, Radboud Alzheimer Centre, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands.
Benno KüstersDepartment of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.
Catharina J M KlijnDepartment of Neurology, Radboud Alzheimer Centre, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands.
Marcel M VerbeekDepartment of Laboratory Medicine, Radboud University Medical Center, Nijmegen, The Netherlands. marcel.verbeek@radboudumc.nl.
Radboud University Medical Center · NLRadboud University Nijmegen · NLUniversity Medical Center Utrecht · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cerebral amyloid angiopathy (CAA) is characterized by the deposition of the amyloid β (Aβ) protein in the cerebral vasculature and poses a major risk factor for the development of intracerebral haemorrhages (ICH). However, only a minority of patients with CAA develops ICH (CAA-ICH), and to date it is unclear which mechanisms determine why some patients with CAA are more susceptible to haemorrhage than others. We hypothesized that an imbalance between matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) contributes to vessel wall weakening. MMP9 plays a role in the degradation of various components of the extracellular matrix as well as of Aβ and increased MMP9 expression has been previously associated with CAA. TIMP3 is an inhibitor of MMP9 and increased TIMP3 expression in cerebral vessels has also been associated with CAA. In this study, we investigated the expression of MMP9 and TIMP3 in occipital brain tissue of CAA-ICH cases (n = 11) by immunohistochemistry and compared this to the expression in brain tissue of CAA cases without ICH (CAA-non-haemorrhagic, CAA-NH, n = 18). We showed that MMP9 expression is increased in CAA-ICH cases compared to CAA-NH cases. Furthermore, we showed that TIMP3 expression is increased in CAA cases compared to controls without CAA, and that TIMP3 expression is reduced in a subset of CAA-ICH cases compared to CAA-NH cases. In conclusion, in patients with CAA, a disbalance in cerebrovascular MMP9 and TIMP3 expression is associated with CAA-related ICH.

Indexed as

AgedAged, 80 and overCerebral Amyloid AngiopathyCerebral HemorrhageFemaleHumansMaleMatrix Metalloproteinase 9Middle AgedTissue Inhibitor of Metalloproteinase-3Matrix Metalloproteinase 9MMP9 protein, humanTIMP3 protein, humanTissue Inhibitor of Metalloproteinase-3Alzheimer’s diseaseAmyloid β proteinCerebral amyloid angiopathyIntracerebral haemorrhageMatrix metalloproteinase 9Tissue inhibitor of metalloproteinases 3

Identifiers

PMID32631441
PMCPMC7336459
OpenAlexW3039378818

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.